[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573480":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":42,"centralContacts":48,"locations":54,"responsibleParty":68,"collaborators":70,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":41,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":41,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":98,"whyStopped":41,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"S-Meth, R-Meth, Racemic Isomer","EXPERIMENTAL","First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine",[13,14,15],"Drug: S-(+)-methamphetamine","Drug: R-(-)-methamphetamine","Drug: 1:1 racemic mixture of two isomers",{"label":17,"type":10,"description":18,"interventionNames":19},"R-Meth, Racemic Isomer, S-Meth","First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Racemic Isomer, S-Meth, R-Meth","First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth",[13,14,15],[25,32,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","S-(+)-methamphetamine","15 mg",[17,21,9],[31],"S-Meth",{"type":26,"name":33,"description":28,"armGroupLabels":34,"otherNames":35},"R-(-)-methamphetamine",[17,21,9],[36],"R-Meth",{"type":26,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"1:1 racemic mixture of two isomers","15 mg R-Meth + 15 mg S-Meth",[17,21,9],null,[43,46],{"name":44,"affiliation":5,"role":45},"Heather K Barkholtz, PhD","PRINCIPAL_INVESTIGATOR",{"name":47,"affiliation":5,"role":45},"David Leinweber, MD",[49],{"name":50,"role":51,"phone":52,"phoneExt":41,"email":53},"Heather Barkholtz, PhD","CONTACT","608-890-1967","hbarkholtz@wisc.edu",[55],{"facility":56,"status":41,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":41},"University of Wisconsin","Madison","Wisconsin","53705","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-89.40123,43.07305,{"lat":66,"lon":65},{"type":69,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[71],{"name":72,"class":73},"U.S. Department of Justice","FED","100573480","phase-1-methamphetamine-isomer-pharmacology-in-humans-100573480",false,"NCT06746831","Methamphetamine Isomer Pharmacology in Humans","The Low-Down on Methamphetamine Isomers: Prevalence and Pharmacology in Humans","Inclusion Criteria:\n\n* Good mental health as determined by self-reported responses to the Psychopathology Screener\n* Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener\n* English-speaking (able to provide consent and complete questionnaires)\n* Written Informed Consent\n\nExclusion Criteria:\n\n* Any serious prior adverse response to sympathomimetic agents or amphetamine analogs\n* History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener\n* Pregnancy or lactation (pregnancy test, if needed)\n* Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)\n* Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.",true,"ALL","21 Years","64 Years",{"count":86,"type":87},17,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.",[93],"Methamphetamine",[95,96,97],"pharmacology","meth","isomers","NOT_YET_RECRUITING","2026-06-29",{"date":101,"type":102},"2026-07-01","ACTUAL",{"date":104,"type":87},"2026-07",{"date":106,"type":87},"2028-03",{"name":5,"class":6},1]